Mucosal invariant T cells combined with inflammatory cytokines were used to identify chronic rhinosinusitis with nasal polyps or without nasal polyps
Abstract
Objective: The present study attempted to analyze the effect of mucosal-associated invariant T (MAIT) combined with inflammatory factors in identifying chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP) that provides a clinical reference.
Methods: In this retrospective study, we enrolled 56 CRSsNP patients, 68 CRSwNP patients, and 60 healthy controls. Flow cytometry was used to detect the frequency of peripheral blood MAIT cells (MAIT+). Serum levels of hs-CRP, IL-1β, and IL-6 were measured by ELISA and automatic blood cell analyzer, and their correlations with MAIT cell alterations were analyzed. The diagnostic effect of MAIT+ combined with hs-CRP, IL-1β, and IL-6 on CRS was analyzed using ROC curves.
Results: Both CRSsNP and CRSwNP patients exhibited significantly reduced MAIT+ frequencies compared to controls (P<0.05), with CRSwNP showing the most pronounced decrease (P<0.05). MAIT+ levels were inversely correlated with hs-CRP, IL-1β, and IL-6 in CRS patients. ROC analysis demonstrated that MAIT+ effectively discriminated CRSsNP (AUC=0.793) and CRSwNP (AUC=0.863) from healthy individuals (P<0.01). After combined with inflammatory factors, the diagnostic effect of MAIT+ on CRSsNP (AUC=0.933) and CRSwNP (AUC=0.939) was further improved.
Conclusion: Detection of MAIT+ combined with inflammatory factors may provide novel biomarkers for CRS subtype identification.
Copyright (c) 2025 Yilong Wang, Yongjun Feng, Jie Song, Zhongjun Mou
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.